Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor
Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor
复制标题
氢氯噻嗪联合环氧合酶2抑制剂治疗先天性肾性尿崩症
DOI：
--
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
U. Alon
中科院分区：
文献类型：
--
作者：
A. Pattaragarn;U. Alon
一个1个月大的男婴表现为发育不良、多尿和严重的高钠性脱水。根据家族史、对加压素缺乏反应及泌尿系统超音波检查正常，诊断为先天性肾源性尿崩症。婴儿对吲哚美辛联合氢氯噻嗪（HCTZ）反应良好，但很快发生胃肠道出血。阿米洛利和托美丁取代吲哚美辛被认为是无效的。用HCTZ（每天3 mg/kg）和罗非昔布（每天1 mg/kg，均分为三个剂量）与低盐配方组合治疗导致尿液游离水损失急剧减少。没有注意到联合用药的副作用。在8.5个月大时，婴儿表现出追赶性生长和正常的神经发育里程碑。我们得出结论，HCTZ/环氧合酶-2抑制剂的组合可以成功地用于治疗婴儿cNDI。
A 1-month-old male infant presented with failure to thrive, polyuria, and severe hypernatremic dehydration. Based on family history, lack of response to vasopressin, and normal sonography of the urinary system, the diagnosis of congenital nephrogenic diabetes insipidus (cNDI) was established. The infant responded well to indomethacin in combination with hydrochlorothiazide (HCTZ), but quickly developed gastrointestinal bleeding. The substitution of indomethacin by amiloride and later by tolmetin was found to be ineffective. Treatment with HCTZ (3 mg/kg per day) and rofecoxib (1 mg/kg per day, both divided into three doses) combined with a low-salt formula resulted in a dramatic decrease in urinary free water losses. No side effects of the combination were noted. At age 8.5 months, the infant demonstrated catch-up growth and normal neurodevelopmental milestones. We conclude that the combination HCTZ/cyclooxygenase-2 inhibitor could be successfully used to treat infantile cNDI.
DOI：
10.1016/s0022-2143(96)90012-8
发表时间：
1996-08
期刊：
The Journal of laboratory and clinical medicine
影响因子：
--
作者：
J. Haas;F. Knox
通讯作者：
J. Haas;F. Knox